Olsen et al. Simoa assays were developed to measure AKT, ERK, and cyclin d concentrations in colon cancer patients. Researchers demonstrated an association between levels of these signaling proteins and mutational BRAF status.
Yoh et al. Researchers developed and validated an enrichment method for tumor-derived extracellular vesicles (EVs) in the blood of lung and breast cancer patients using Simoa, providing new insights into enrichment of specific EV subtypes for liquid biopsy.
Oncology
Publication Brief Cancer therapy-associated neurotoxicities can exert debilitating effects on patients and negatively impact the course of cancer treatment. There is a critical need for accurate biomarker tests that could…
Oncology
Brochure Extracellular vesicles (EVs) are involved in the pathogenesis of many diseases, including cancer development and neurodegeneration. Although their application in liquid biopsy is promising, there are several challenges in…
Oncology
Publication Brief The ability to measure oncology biomarkers at ultra-low levels using Simoa® technology holds great promise for cancer research and clinical practice. Simoa® immunoassays can potentially serve as tools…
Simoa, an ultra-sensitive immunoassay technology allows detection of proteins and nucleic acids at lowest possible levels.
